Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: Differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use

Drug Safety

Volumn 29, Issue 11, 2006, Pages 1087-1100

  Sachs, Bernhardt ^a,b   Riegel, Stefan ^a   Seebeck, Jörg ^a   Beier, Rainer ^a   Schichler, Dagmar ^a,b   Barger, Antina ^a   Merk, Hans F ^b   Erdmann, Stephan ^b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DYSPNEA; FEMALE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIA; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SHOCK; THROAT TIGHTNESS; WORLD HEALTH ORGANIZATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; FEMALE; FLUOROQUINOLONES; GERMANY; HUMANS; MALE; MIDDLE AGED;

EID: 33845493047     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200629110-00008     Document Type: Article

References (30)

1. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817
2. Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opin Allergy Clin Immunol 2003; 3: 275-81
3. Ho DY, Song YC, Wang CC. Anaphylactoid reaction to ciprofloxacin. Ann Pharmacother 2003; 37: 1018-23
4. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials. Drug Saf 2003; 26: 109-20
5. Davies H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041-3
6. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin North Am 2004; 24: 345-56
7. Leone R, Conforti A, Venegoni M, et al. Drug-induced anaphylaxis. Drug Saf 2005; 28: 547-56
8. Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113: 155-60
9. Blayac JP, Hillaire-Buys D, Pinzani V. Fluoroquinolones and anaphylaxis. Thérapie 1996; 51: 417-8
10. Meyboom RHB, Egberts ACG, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355-65
11. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12: 271-81
12. van der Klauw MM, Wilson JHP, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in the Netherlands (1974-1994) and review of the literature. Clin Exp Allergy 1996; 26: 1355-63
13. Castel JM, Figueras A, Pedrós C, et al. Stimulating adverse drug reaction reporting. Drug Saf 2003; 26: 1049-55
14. Evans SJW, Waller PC, David S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6
15. International Collaborative Study of Severe Anaphylaxis. An epidemiologic study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. Epidemiology 1998; 9: 141-6
16. International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf 2003; 12: 195-202
17. Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, october 2003. J Allergy Clin Immunol 2004; 113: 832-6
18. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9
19. Schwabe und Paffrath, editors. Arzneimittelverordnungsreporte. Berlin: Springer Verlag, 1994-2004
20. Janhsen K. Public-Health-Forschung mit Arzneimitteldaten gesetzlicher Krankenkassen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 6: 521-5
21. Thiessard F, Roux E, Miremont-Salame G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf 2005; 28: 731-40
22. Weber JCP. Epidemiology of adverse drug reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research. Vol. 6. New York: Raven Press, 1984
23. Schnyder B, Caduff B. Fluoroquinolone und Tendinopathien: Ein Klasseneffekt? Schweiz Ärztezg 2003; 84: 29-35
24. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50
25. Alemán AM, Quirce S, Cuesta J, et al. Anaphylactoid reaction caused by moxifloxacin. J Invest Allergol Clin Immunol 2002; 12: 67-8
26. Nori S, Nebesio C, Brashear R, et al. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol 2004; 140: 1537-8
27. Bozkurt B, Karakaya G, Kalyoncu AF. Tolerability of moxifloxacin in patients with antibiotic hypersensitivity. Allergol Immunopathol (Madr) 2005; 33: 38-41
28. Kurata M, Kasuga Y, Nanba E, et al. Flush induced by fluoroquinolones in canine skin. Inflamm Res 1995; 44: 461-5
29. Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999; 57: 363-73
30. Wurtz RM, Abrams D, Becker S, et al. Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients. Lancet 1989; I: 955-6